

O I P E DOCKET NO	O. 17243CIP3(AP)	PATENT.	
/	IN THE UNITED STATES P.	PATENT AND TRADEMARK OFFICE	П
MAR 1 2 2002	cant: Chow et al.) I hereby certify that this correspondence is being deposited with the United States Postal Service as Tist	П
Sectial 1		deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Petiton to Correct Inventorship, Assistant Commissioner for Patents, Box Inventorship Correction, Washington,)
TRADEMA Filed:	March 21, 2001	2/28/2002 \(\frac{1}{2}	<u>П</u>
For:	COMPOUNDS AND METHOD OF	DONNIE FERGUSEN &	\leq
TREAT	MENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE) FONNIE FERGUSAN R [Π
AT AL	PHA 2B OR 2B/2C ADRENERGIC RECEPTORS) Printed Name of Person Making Deposit	
	Art Unit: 1626	Bonnie Joseph	_
Examin	ner: Floyd D. Higel	Signature / 2/2-8/2-002_	
Art Un	nit:)1626	Date of Signature	

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Dario G. Gomez as an inventor in the above-referenced patent application . ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan Sales, Inc.

Respectfully submitted,

Martin A. Voet Assistant Secretary Allergan Sales, Inc. 2525 Dupont Drive Invine CA 92612

DOCKET NO. 17243CIP3(AP) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In the United States

STATEMENT OF DARIO G. GOMEZ

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

I, Dario G. Gomez, am an inventor of the subject matter claimed in the above-referenced patent application.

At the time the invention was made I was employed by Allergan, Inc., the parent company of the assignee Allergan Sales, Inc. I was unaware that this continuing application was filed until after the filing date, and therefore had no opportunity to advise Allergan that the inventor information, including the list of inventors, was incomplete. Thus, the incorrect naming of the inventive entity in this patent application was made without deceptive intent on my part; moreover, it is my understanding that such incorrect indication of inventors was an inadvertent error made when the patent application was filed.

Respectfully submitted,

Dated: 02/19/02

Dario G. Gomez